ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2170

I Know It When I See It! Improving Visual Diagnosis Education in Rheumatology Fellowship Training
Abstract Number: 0903

Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling
Abstract Number: 0082

IBI3011, a Humanized anti-IL1RAP Monoclonal Antibody, Inhibits IL1, IL33, IL36-driven Inflammation Pathway, and Attenuates Inflammation in Preclinical Inflammatory Disease Model
Abstract Number: 0562

Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Abstract Number: 2599

Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites
Abstract Number: 0040

Identification Of A Novel, Expressed, Alternatively Spliced FCER1G Protein That Inhibits Receptor Function
Abstract Number: 2399

Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
Abstract Number: 0861

Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Abstract Number: 1767

Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis
Abstract Number: 2140

Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry
Abstract Number: 0067

Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
Abstract Number: 0997

Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 
Abstract Number: 0526

Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
Abstract Number: 1985

Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
Abstract Number: 0378

Identifying Patterns of Telemedicine Readiness and Digital Health Literacy in Rheumatoid Arthritis Patients: A Latent Class Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].